Medicine · 2026
Individualized treatment strategies for primary hepatic neuroendocrine carcinoma: Two case reports and literature review (A CARE-compliant case report).
СтатьяКлинический случайОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Haiyang, Chen Kai, Xiao Heng, Lan Xiang
Аннотация
RATIONALE: Primary hepatic neuroendocrine carcinoma (PHNET) is an exceptionally rare malignancy with limited standardized treatment options.
PATIENT CONCERNS: Two patients presented with incidentally detected hepatic masses and nonspecific gastrointestinal symptoms.
DIAGNOSES: Case 1 was diagnosed as primary hepatic neuroendocrine carcinoma (NEC, G3), and Case 2 as primary hepatic large-cell neuroendocrine carcinoma (LCNEC, G3), based on histopathology and immunohistochemistry after excluding extrahepatic origins.
INTERVENTIONS: Case 1 received transarterial chemoembolization (TACE), etoposide-cisplatin chemotherapy, hepatic arterial infusion chemotherapy (HAIC), and octreotide. Case 2 underwent 3 cycles of drug-eluting bead TACE (d-TACE), HAIC, and long-acting octreotide for symptomatic control of diarrhea.
OUTCOMES: Case 1 experienced progressive disease and died of sepsis. Case 2 achieved significant tumor regression, allowing curative resection. No recurrence was observed at one-month follow-up.
LESSONS: The combination of d-TACE, HAIC, and octreotide may provide a potential downstaging approach for unresectable PHNET, but evidence remains preliminary and hypothesis-generating.
PATIENT CONCERNS: Two patients presented with incidentally detected hepatic masses and nonspecific gastrointestinal symptoms.
DIAGNOSES: Case 1 was diagnosed as primary hepatic neuroendocrine carcinoma (NEC, G3), and Case 2 as primary hepatic large-cell neuroendocrine carcinoma (LCNEC, G3), based on histopathology and immunohistochemistry after excluding extrahepatic origins.
INTERVENTIONS: Case 1 received transarterial chemoembolization (TACE), etoposide-cisplatin chemotherapy, hepatic arterial infusion chemotherapy (HAIC), and octreotide. Case 2 underwent 3 cycles of drug-eluting bead TACE (d-TACE), HAIC, and long-acting octreotide for symptomatic control of diarrhea.
OUTCOMES: Case 1 experienced progressive disease and died of sepsis. Case 2 achieved significant tumor regression, allowing curative resection. No recurrence was observed at one-month follow-up.
LESSONS: The combination of d-TACE, HAIC, and octreotide may provide a potential downstaging approach for unresectable PHNET, but evidence remains preliminary and hypothesis-generating.